Haleon plc: 2024 Q3 Trading Statement
31 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its Q3 trading update for the year ending 31 December 2024 is available at: http://www.rns-pdf.londonstockexchange.com/rns/3035K_1-2024-10-30.pdf
The Q3 trading update will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Tobias Hestler, Chief Financial Officer at 9:00am GMT (10:00am CET) on 31 October 2024, which can be accessed at www.haleon.com/investors/.
For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:
UK:
|
+44 800 358 1035
|
US:
|
+1 855 979 6654
|
All other:
|
+44 20 3936 2999
|
Passcode:
|
401552
|
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
Investors
|
Media
|
Rakesh Patel
|
+44 7552 484646
|
Zoë Bird
|
+44 7736 746167
|
Emma White
|
+44 7823 523562
|
Gemma Thomas
|
+44 7985 175048
|
Email: [email protected]
|
Email: [email protected]
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.